Literature DB >> 28655284

Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis.

Dan Siskind1,2, Victor Siskind3, Steve Kisely1,2.   

Abstract

Clozapine is the most effective antipsychotic for the 25% to 33% of people with schizophrenia who are treatment resistant, but not all people achieve response. Using data from a previously published clozapine systematic review and meta-analysis, we explored the proportion of people who achieved response and examined the absolute and percentage change in Positive and Negative Syndrome Scale (PANSS) scores. Overall, 40.1% (95% confidence interval [CI], 36.8%-43.4%) responded, with a mean reduction in PANSS of 22.0 points (95% CI, 20.9-23.1), a reduction of 25.8% (95% CI, 24.7%-26.9%) from baseline. These reductions are clinically meaningful. A 40% response rate to clozapine suggests that 12% to 20% of people with schizophrenia will be ultra-resistant.

Entities:  

Keywords:  PANSS; clozapine; response; schizophrenia; treatment-resistant

Mesh:

Substances:

Year:  2017        PMID: 28655284      PMCID: PMC5697625          DOI: 10.1177/0706743717718167

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  28 in total

1.  Clozapine Underutilization in the Treatment of Schizophrenia: How Can Clozapine Prescription Rates Be Improved?

Authors:  Jan P A M Bogers; Peter F J Schulte; Daniel Van Dijk; Bert Bakker; Dan Cohen
Journal:  J Clin Psychopharmacol       Date:  2016-04       Impact factor: 3.153

2.  An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis.

Authors:  Ofer Agid; Tamara Arenovich; Gautam Sajeev; Robert B Zipursky; Shitij Kapur; George Foussias; Gary Remington
Journal:  J Clin Psychiatry       Date:  2011-03-08       Impact factor: 4.384

3.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

4.  Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group.

Authors:  G Bondolfi; H Dufour; M Patris; J P May; U Billeter; C B Eap; P Baumann
Journal:  Am J Psychiatry       Date:  1998-04       Impact factor: 18.112

5.  Risperidone versus clozapine in treatment-resistant schizophrenia: a randomized pilot study.

Authors:  K Wahlbeck; M Cheine; K Tuisku; A Ahokas; G Joffe; R Rimón
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2000-08       Impact factor: 5.067

6.  Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison.

Authors:  S Kumra; J A Frazier; L K Jacobsen; K McKenna; C T Gordon; M C Lenane; S D Hamburger; A K Smith; K E Albus; J Alaghband-Rad; J L Rapoport
Journal:  Arch Gen Psychiatry       Date:  1996-12

7.  Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia.

Authors:  Istvan Bitter; Martin R K Dossenbach; Shlomo Brook; Peter D Feldman; Stephen Metcalfe; Carlo A Gagiano; János Füredi; György Bartko; Zoltan Janka; Csaba M Banki; Gabor Kovacs; Alan Breier
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2004-01       Impact factor: 5.067

8.  Cerebral D2 and 5-HT2 receptor occupancy in Schizophrenic patients treated with olanzapine or clozapine.

Authors:  Rosa Maria Moresco; Roberto Cavallaro; Cristina Messa; Daniele Bravi; Clara Gobbo; Laura Galli; Giovanni Lucignani; Cristina Colombo; Giovanna Rizzo; Isabella Velonà; Enrico Smeraldi; Ferruccio Fazio
Journal:  J Psychopharmacol       Date:  2004-09       Impact factor: 4.153

9.  A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia.

Authors:  Herbert Y Meltzer; William V Bobo; Ajanta Roy; Karu Jayathilake; Yuejin Chen; Aygun Ertugrul; A Elif Anil Yağcioğlu; Joyce G Small
Journal:  J Clin Psychiatry       Date:  2008-02       Impact factor: 4.384

10.  Minimum clinically important difference in the Positive and Negative Syndrome Scale with data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE).

Authors:  Eric D A Hermes; Daniel Sokoloff; T Scott Stroup; Robert A Rosenheck
Journal:  J Clin Psychiatry       Date:  2012-04       Impact factor: 4.384

View more
  58 in total

1.  Clozapine response trajectories and predictors of non-response in treatment-resistant schizophrenia: a chart review study.

Authors:  Parita Shah; Yusuke Iwata; Eric E Brown; Julia Kim; Marcos Sanches; Hiroyoshi Takeuchi; Shinichiro Nakajima; Margaret Hahn; Gary Remington; Philip Gerretsen; Ariel Graff-Guerrero
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-08-19       Impact factor: 5.270

2.  Association With Hospitalization and All-Cause Discontinuation Among Patients With Schizophrenia on Clozapine vs Other Oral Second-Generation Antipsychotics: A Systematic Review and Meta-analysis of Cohort Studies.

Authors:  Takahiro Masuda; Fuminari Misawa; Masayuki Takase; John M Kane; Christoph U Correll
Journal:  JAMA Psychiatry       Date:  2019-10-01       Impact factor: 21.596

3.  Clozapine Combination and Augmentation Strategies in Patients With Schizophrenia -Recommendations From an International Expert Survey Among the Treatment Response and Resistance in Psychosis (TRRIP) Working Group.

Authors:  Elias Wagner; John M Kane; Christoph U Correll; Oliver Howes; Dan Siskind; William G Honer; Jimmy Lee; Peter Falkai; Thomas Schneider-Axmann; Alkomiet Hasan
Journal:  Schizophr Bull       Date:  2020-12-01       Impact factor: 9.306

Review 4.  Delayed Initiation of Clozapine Continues to Be a Substantial Clinical Concern.

Authors:  Alexander Panickacheril John; Elvin Kay Fon Ko; Arun Dominic
Journal:  Can J Psychiatry       Date:  2018-04-22       Impact factor: 4.356

5.  Chronic low-grade peripheral inflammation is associated with ultra resistant schizophrenia. Results from the FACE-SZ cohort.

Authors:  G Fond; O Godin; L Boyer; F Berna; M Andrianarisoa; N Coulon; L Brunel; E Bulzacka; B Aouizerate; D Capdevielle; I Chereau; T D'Amato; C Dubertret; J Dubreucq; C Faget; S Leignier; C Lançon; J Mallet; D Misdrahi; C Passerieux; R Rey; A Schandrin; M Urbach; P Vidailhet; P M Llorca; F Schürhoff; M Leboyer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-05-28       Impact factor: 5.270

6.  Clozapine and Psychosocial Function in Schizophrenia: A Systematic Review and Meta-Analysis.

Authors:  Andrew T Olagunju; Scott R Clark; Bernhard T Baune
Journal:  CNS Drugs       Date:  2018-11       Impact factor: 5.749

7.  Identifying and characterizing treatment-resistant schizophrenia in observational database studies.

Authors:  Linus Jönsson; Jacob Simonsen; Cecilia Brain; Steven Kymes; Louise Watson
Journal:  Int J Methods Psychiatr Res       Date:  2019-04-07       Impact factor: 4.035

8.  Predictors of Treatment-Resistant and Clozapine-Resistant Schizophrenia: A 12-Year Follow-up Study of First-Episode Schizophrenia-Spectrum Disorders.

Authors:  Sherry Kit Wa Chan; Hei Yan Veronica Chan; William G Honer; Tarun Bastiampillai; Yi Nam Suen; Wai Song Yeung; Ming Lam; Wing King Lee; Roger Man King Ng; Christy Lai Ming Hui; Wing Chung Chang; Edwin Ho Ming Lee; Eric Yu Hai Chen
Journal:  Schizophr Bull       Date:  2021-03-16       Impact factor: 9.306

Review 9.  The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses.

Authors:  Peter M Haddad; Christoph U Correll
Journal:  Ther Adv Psychopharmacol       Date:  2018-10-08

10.  Treatment Capacity and Clinical Outcomes for Patients With Schizophrenia Who Were Treated With Electroconvulsive Therapy: A Retrospective Cohort Study.

Authors:  Joanne E Plahouras; Gerasimos Konstantinou; Tyler S Kaster; Daniel Z Buchman; George Foussias; Zafiris J Daskalakis; Daniel M Blumberger
Journal:  Schizophr Bull       Date:  2021-03-16       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.